Editorial

  • HOME
  • ARTICLE CATEGORY
  • Editorial
Editorial
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective
Carlos Jose Pirola, Silvia Sookoian
Clin Mol Hepatol. 2024;30(2):174-176.   Published online February 5, 2024
View: 1711   Download: 51  Crossref: 1
1884
Steatotic liver disease: Know your enemies
Lung-Yi Mak
Clin Mol Hepatol. 2024;30(2):171-173.   Published online February 2, 2024
View: 1684   Download: 64  Crossref: 1
JCAD, a new potential therapeutic target in cholestatic liver disease
Byoung Kuk Jang
Clin Mol Hepatol. 2024;30(2):166-167.   Published online March 8, 2024
View: 1577   Download: 33  Crossref: 1
Linvencovir: Paving the way for functional cure in hepatitis B
Jiwon Yang, Jonggi Choi
Clin Mol Hepatol. 2024;30(2):164-165.   Published online March 6, 2024
View: 1594   Download: 47
Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma
Ji Eun Han, Hyo Jung Cho
Clin Mol Hepatol. 2024;30(2):160-163.   Published online February 28, 2024
View: 1676   Download: 41
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
Chen-Te Huang, Tai-Chung Tseng
Clin Mol Hepatol. 2024;30(2):154-156.   Published online February 22, 2024
View: 1428   Download: 43  Crossref: 1
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol. 2024;30(2):150-153.   Published online February 22, 2024
View: 2167   Download: 61
Toward hepatitis C virus elimination using artificial intelligence
Moon Haeng Hur, Jeong-Hoon Lee
Clin Mol Hepatol. 2024;30(2):147-149.   Published online February 23, 2024
View: 1735   Download: 58  Crossref: 1
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clin Mol Hepatol. 2023;29(4):980-983.   Published online August 16, 2023
View: 1751   Download: 86
Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
Sang Min Yoon
Clin Mol Hepatol. 2023;29(4):977-979.   Published online August 31, 2023
View: 1357   Download: 38
Adding to the confusion in more than just the name
Jacob George
Clin Mol Hepatol. 2023;29(4):973-976.   Published online September 18, 2023
View: 1600   Download: 64  Web of Science: 4  Crossref: 5
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clin Mol Hepatol. 2023;29(3):690-692.   Published online May 30, 2023
View: 2011   Download: 88  Web of Science: 1  Crossref: 1
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clin Mol Hepatol. 2023;29(2):414-416.   Published online February 28, 2023
View: 4193   Download: 66
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):411-413.   Published online March 6, 2023
View: 2189   Download: 47  Web of Science: 1  Crossref: 1
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Ji-Won Park, Ki Tae Suk
Clin Mol Hepatol. 2023;29(2):408-410.   Published online March 16, 2023
View: 2455   Download: 69  Web of Science: 2  Crossref: 2
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
Clin Mol Hepatol. 2023;29(2):404-407.   Published online March 14, 2023
View: 2752   Download: 75  Web of Science: 2  Crossref: 2
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Kee-Huat Chuah, Wah-Kheong Chan
Clin Mol Hepatol. 2023;29(2):401-403.   Published online February 28, 2023
View: 2562   Download: 62  Web of Science: 1  Crossref: 2
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Maamon Basheer, Mohamed Naffaa, Nimer Assy
Clin Mol Hepatol. 2023;29(2):398-400.   Published online February 13, 2023
View: 2953   Download: 128
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clin Mol Hepatol. 2023;29(2):394-397.   Published online April 1, 2023
View: 2604   Download: 84  Web of Science: 1
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Philipp Kasper, Münevver Demir, Hans-Michael Steffen
Clin Mol Hepatol. 2023;29(2):390-393.   Published online March 20, 2023
View: 2555   Download: 58  Web of Science: 2  Crossref: 2
Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2023;29(2):384-389.   Published online March 14, 2023
View: 3032   Download: 77  Web of Science: 1  Crossref: 1
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol. 2023;29(2):377-380.   Published online March 9, 2023
View: 2485   Download: 96  Web of Science: 2  Crossref: 1
The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clin Mol Hepatol. 2023;29(2):374-376.   Published online March 6, 2023
View: 2361   Download: 65

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 524
TOTAL : 1881293
Close layer